85952-30-3

Usage

Uses

Used in Pharmaceutical Industry:
(3,4-DICHLORO-PHENYL)-METHANESULFONYL CHLORIDE is used as a building block for the synthesis of various drugs and biologically active compounds, due to its ability to introduce the methanesulfonyl group into organic molecules, which is essential for the development of new pharmaceutical agents.
Used in Organic Synthesis:
(3,4-DICHLORO-PHENYL)-METHANESULFONYL CHLORIDE is used as a reagent for the synthesis of sulfonyl chlorides, sulfonamides, and sulfonates, contributing to the advancement of organic chemistry and the creation of novel chemical entities.
Used in Research and Development:
(3,4-DICHLORO-PHENYL)-METHANESULFONYL CHLORIDE is used as a research tool for studying organic reaction mechanisms and the development of new synthetic methodologies, aiding in the understanding of chemical processes and the innovation of more efficient synthetic routes.

InChI:InChI=1/C7H5Cl3O2S/c8-6-2-1-5(3-7(6)9)4-13(10,11)12/h1-3H,4H2

Upstream product

• 102-47-6 3,4-Dichlorophenylmethyl chloride 
• 18880-04-1 3,4-dichlorobenzyl bromide 
• 22816-60-0 S-(3,4-dichlorobenzyl)isothiourea hydrochloric acid salt 
• 111875-15-1 sodium (3,4‐dichlorophenyl)methanesulfonate 

Downstream Products

• 88691-42-3 [(E)-2-(2,4-Dichloro-phenyl)-vinyl]-trimethyl-silane 
• 111874-97-6 C-(3,4-Dichloro-phenyl)-N-(4-phenyl-butyl)-methanesulfonamide 
• 111874-94-3 C-(3,4-Dichloro-phenyl)-N-(3-phenyl-propyl)-methanesulfonamide 
• 111874-92-1 C-(3,4-Dichloro-phenyl)-N-[2-(3,4-dimethoxy-phenyl)-ethyl]-methanesulfonamide 
• 111874-91-0 C-(3,4-Dichloro-phenyl)-N-[2-(4-methoxy-phenyl)-ethyl]-methanesulfonamide 
• 111874-85-2 N-Benzyl-C-(3,4-dichloro-phenyl)-methanesulfonamide 
• 683812-94-4 methyl 4-{2-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]ethoxy}benzoate 
• 111874-96-5 C-(3,4-Dichloro-phenyl)-N-(2-methyl-3-phenyl-propyl)-methanesulfonamide 

Relevant academic research and scientific papers

AMINO ALCOHOL COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

In our continuing efforts to develop novel c-Met inhibitors as potential anticancer candidates, a series of new N-sulfonylamidine derivatives were designed, synthesized via Cu-catalyzed multicomponent reaction (MCR) as the key step, and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (A549, HT-29, MKN-45 and MDA-MB-231). Most of the target compounds showed moderate to significant potency at both the enzyme-based and cell-based assay and possessed selectivity for A549 and HT-29 cancer cell lines. The preliminary SAR studies demonstrated that compound 26af (c-Met IC50 = 2.89 nM) was the most promising compound compared with the positive foretinib, which exhibited the remarkable antiproliferative activities, with IC50 values ranging from 0.28 to 0.72 μM. Mechanistic studies of 26af showed the anticancer activity was closely related to the blocking phosphorylation of c-Met, leading to cell cycle arresting at G2/M phase and apoptosis of A549 cells by a concentration-dependent manner. The promising compound 26af was further identified as a relatively selective inhibitor of c-Met kinase, which also possessed an acceptable safety profile and favorable pharmacokinetic properties in BALB/c mouse. The favorable drug-likeness of 26af suggested that N-sulfonylamidines may be used as a promising scaffold for antitumor drug development. Additionally, the docking study and molecular dynamics simulations of 26af revealed a common mode of interaction with the binding site of c-Met. These positive results indicated that compound 26af is a potential anti-cancer candidate for clinical trials, and deserves further development as a selective c-Met inhibitor.

SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF

Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

Synthesis of Fused Heterocycles: 1,2,3,4-Tetrahydroisoquinolines and Ring Homologues via Sulphonamidomethylation

The title heterocycles (3) have been obtained by a two-step synthesis; namely an initial intramolecular sulphonamidomethylation of N-aralkylsulphonamides (1) in acid media followed by desulphonylation of compounds (2) under moderate conditions, either by reduction or acid hydrolysis.Generally both steps gave good or high yields of compounds (3) variously substituted in the aromatic ring and with a six-, seven-, or eight-membered heterocyclic ring.